Edward M. Tavel, Jr. M.D.

Pain Specialists of Charleston
2695 Elms Plantation Blvd – Suite A and Suite D
Charleston, SC 29406
Clinic: 843-818-1181 ◆ Research: 843-725-5067 ◆ Fax: 843-818-1145

Education

1981-1985	Davidson College, Davidson, NC Bachelor of Science, Pre-Med
1985-1989	Medical University of South Carolina, Charleston, SC MD

Residency

1989 – 1990	Internship Roanoke Memorial Hospital, Roanoke VA
1990 - 1993	Anesthesiology University of North Carolina, Chapel Hill, NC (Residency)
1992 - 1993	University of North Carolina, Chapel Hill, NC (Chief Resident)

Professional Experience

Pain Specialists of Charleston, PA,
Owner/Medical Director 2009 – Present

Pain Care Physicians of Charleston
Managing Partner, 2006-2009

Medical Executive Committee
Trident Regional Medical Center, 2005-2009

Palmetto Anesthesia of Charleston
Managing Partner, 2003-2009

Trident Anesthesia Group
Member: 1993-2009, Partner: 1996-2009, Managing Partner: 2003-2009

Relevant Affiliations

The Academy of Pharmaceutical Physicians and Investigators (**APPI**), 2010 – Present

Society of Clinical Research Associates (**SOCRA**), 2010 – Present

Drug Information Association (**DIA**), 2010 – Present

Atlanta Center for Clinical Research, Corp., 2008 - Present

International Spinal Intervention Society (ISIS), 2006-Present

American Society of Interventional Pain Management, 2006-Present

American Society of Regional Anesthesia

Licensures and Certifications

South Carolina Board of Medical Examiners, 1993 - Present

Board Certified in Anesthesiology, 1994 – Present

Board Certified in Pain Management, 2009 - Present

Posters and Publications

Tavel, E. Dunteman, D. Sweeney, M.
Safety and Efficacy of Gastroretentive Gabapentin in Real-World Clinical Practice for Treatment of Patients with Postherpetic Neuralgia (PHN). Poster session presented at: The American Academy of Pain Medicine's 29th Annual Conference; 2013 April 9-14;
Ft. Lauderdale, Florida

Tavel, E. Brownlow, C. Howes, G. Haley, T. Creamer, M. Ghodsi, A. Rosenberg, J. Washburn, S.
The validation of a multi sensor on-body monitoring system to objectively measure changes in physical function and sleep, in patients undergoing a spinal cord stimulation trial; Interim results. Poster session presented at: From Innovation to Reality. 16th Annual North American Neuromodulation Society; 2012 December 6-9;
Las Vegas Nevada

Research-Specific Training

DIA Annual Conference – June 2011

Good Clinical Practices Training – 2010, 2011

SOCRA Annual Conference – 2010 Course Series 10001

NIH Online Training in the Protection of Human Research Subjects – 2008, 2010 cert # 542183

CITI Course for Human Subjects Research – 2008, 2010, 2013 cert # 9860878

Clinical Research Experience

- "A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of XXXX in the Treatment of Opioid-induced Constipation in Subjects with Non-malignant Chronic Pain Receiving Opioid Therapy," September 2013-present
  Principal Investigator

- "A Phase 3b, Randomized, Double-Blind, Placebocontrolled, Parallel-Treatment Group, Multicenter Efficacy And Safety Study Of XXXX In Subjects With Anal Fissure," May 2013 – Present
  Principal Investigator

- "Cardiovascular Safety & Renal Microvascular Outcome with XXXX in Patients with Type 2 Diabetes Mellitus at High Cardiovascular Risk," April 2013 – Present
  Principal Investigator

- "A Phase 3, Open-Label, Long-Term Study to Evaluate the Safety, Tolerability and Analgesic Efficacy of XXXX in Subjects with Moderate to Severe Chronic Pain Requiring Continuous Around-the-Clock Opioid Analgesia for an Extended Period of Time," January 2013 – Present
  Principal Investigator

- "A Phase 2, A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety and Efficacy of a Single Treatment of XXXX in Patients With Postherpetic Neuralgia," January 2013 – Present
  Principal Investigator

- "A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of XXXX in Patients with Post-Herpetic Neuralgia (PHN)," January 2013 – Present
  Principal Investigator

- "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-term Safety and Tolerability of XXXX for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Non-Cancer Pain," January 2013 - Present
  Principal Investigator

- "A Randomized, Double-blind, Double-dummy, Placebo-controlled, Active-controlled, Parallel-group, Multicenter Trial of XXXX to Assess the Analgesic Efficacy and the Management of Opioid-induced Constipation in Opioid-experienced Subjects with Controlled Moderate to Severe Chronic Low Back Pain and a History of Opioid-induced Constipation who Require Around-the-clock Opioid Therapy," October 2012-Present
  Principal Investigator

- "A Multicenter, 12-Week, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study To Determine The Efficacy And Safety Of XXXX In Subjects With Moderate To Severe Chronic Low Back Pain"," June 2012-Present
  Principal Investigator

- "A Phase 3 , Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Efficacy Study of XXXX Versus Placebo in Opioid-Experienced and Opioid-Naïve Subjects with Moderate-to-Severe Chronis Low Bank Pain," August 2012 - Present
  Principal Investigator

- "A Phase 3, Open Label Safety Study of XXXX in Subjects with Osteoarthritis or Chronic Low Back Pain," May 2012 - Present
  Principal Investigator

- "A Phase 2 Enriched Enrollment, Randomized-Withdrawal, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Tolerability and Safety of XXXX in Opioid-Naïve Subjects with Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee," June 2012 – Present
  Principal Investigator
  Recognized for first place titration and randomization of study subjects
  Recognized as second highest screening study-wide

- "An Open-Label 52-week Study to Assess the Long-Term Safety of XXXX in Patients with Opioid-Induced Constipation," May 2011- January 2013
  Principal Investigator
  Recognized for exceptional strategies in identifying, pre-screening and screening patients
  Recognized as high enroller 1st month of enrollment
  Recognized for highest enroller in our region

- "A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study with an Open-label Run to Assess the Efficacy and Safety of XXXX in Subjects with Moderate to Severe Chronic Low Back Pain," 2011-present
  Principal Investigator
  Recognized as high enroller

- "A Phase 4, Open Label, Study of Safety and Effectiveness of XXXX Tablets in the Treatment of Patients with Post-herpetic Neuralgia in Clinical Practice," 2011-present
  Principal Investigator
  Enrollment goal reached in 10 days
  Highest enroller overall to date

- A Phase 2b, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of XXXX in Subjects With Opioid-Induced Constipation," December 2011-2012
  Principal Investigator
  Recognized as top three in screening and enrollment in the United States

- "A Multi-Centered Evaluation of Patients with Chronic Pain of the Trunk and/or Limbs using Paddle Lead(s). November 2011 - Present
  Principal Investigator
  Recognized as top enrollers nationwide (combined Q1 and Q2 in 2012)
  Reached sponsor enrollment goal within 4 months
  Enrollment goal doubled by sponsor

- *"*A Multi-Centered Evaluation of Patients with Chronic Pain of the Trunk and/or Links using Paddle Lead(s); Validation of a Multi-Sensor On-Body Monitoring System to Objectively Measure Changes in Physical Function and Sleep in Patients Undergoing XXXX," June 2012 - Present
  Principal Investigator
  Selected for sub-trial based on stellar performance, outcomes and data within primary study

- "A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XXXX in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)" 2010-2012
  Principal Investigator

- "A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XXXX in Patients with Non-Cancer-Related Pain and Opioid-Induced Constipation (OIC)" 2011-December 2012
  Principal Investigator

- "An Evaluation of the Burden of Illness among Adults in the United States with Peripheral and Central Neuropathic Pain", Oct. 2011
  Principal Investigator
  Enrollment goal reached within 3 weeks
  Tripled enrollment goal set by sponsor

- "A Multi-center, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy and Safety of XXXX in Subjects with Opioid-Induced Bowel Dysfunction", 2010-2011
  Principal Investigator
  Recognized as high enroller

- "A Multicenter, Randomized, Double Blind, Parallel-Group Study of Cardiovascular Safety in Osteoarthritis or Rheumatoid Arthritis Patients With or at High Risk for Cardiovascular Disease Comparing Three Non-Steroidal Medications", 2010-present
  Principal Investigator
  Recognized as high enroller - Second highest enroller WORLD WIDE for August 2011
  Recognized as having high level of subject retention

- "A Multi-center, Randomized, Double-blind, Placebo-controlled Study an Open-label Run-in to Assess the Efficacy, Tolerability, and Safety XXXX or XXXX Compared to Placebo in Opioid-Naïve Subjects with Moderate to Severe Chronic Pain due to Osteoarthritis of the Knee", 2008-2009
  Principal Investigator